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Systematic review of the treatment of established recurrent
hepatitis C with pegylated interferon in combination with ribavirinq
Marina Berenguer*
Hepatogastroenterology Service, Hospital La Fe, Valencia, Spain and CIBEREHD, SpainThe aim of our study was to conduct a systematic review of studies evaluating antiviral therapy with pegylated interferon
(PEG-IFN) alfa in combination with ribavirin for the management of recurrent hepatitis C after liver transplantation.
Data sources included electronic databases and a manual search. Studies evaluating the eﬃcacy and tolerability of
PEG-IFN alfa with ribavirin in patients with recurrent hepatitis C were selected for inclusion. The information extracted
from each of the selected publications included study design details, patient characteristics, treatment regimens and eﬃ-
cacy and tolerability end points. Nineteen studies including 611 patients were identiﬁed. PEG-IFN alfa-2b was used in 16
studies. The mean rate of SVR was 30.2% (range, 8–50%). Dose reduction and discontinuation of treatment were common
in these studies (73% and 27.6%, respectively). The lack of an early virologic response (EVR) at 3 months of therapy was
the most frequently described predictive factor of nonresponse. Treatment discontinuation and dose reductions due to
adverse events were frequent and possibly represent important obstacles to attainment of SVR. EVR at 3 months of treat-
ment should be considered an important predictor of treatment outcome.
 2008 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
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The need to optimize management of hepatitis C
patients is one of the most pressing issues facing trans-
plant physicians. Hepatitis C virus (HCV)-related allo-
graft cirrhosis occurs in 20–30% of liver transplant
recipients within 5 years after surgery, frequently
causing allograft failure and need for retransplantation
[1,2]. Strategies that may help avoid this disease course
include the prevention of either viral or disease0168-8278/$34.00  2008 European Association for the Study of the Liver.
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hepatitis C [1–3]. Prevention of graft reinfection may
be achieved through eradication of the virus by use of
antiviral therapy before transplantation and use of hep-
atitis C immunoglobulins [4–7]. Additionally, after
transplantation, antiviral therapy can be used either pre-
emptively to prevent allograft injury in the ﬁrst weeks
[8–10] or, more commonly, to prevent progression to cir-
rhosis in patients with recurrent hepatitis.
Management of chronic hepatitis C in liver transplant
recipients with recurrent hepatitis C has improved sig-
niﬁcantly during the past decade. [1–3,11–32]. The best
results published to date were obtained with pegylated
IFN (PEG-IFN) alfa in combination with ribavirin
[3,13–32]. Unfortunately, most of these studies are either
open-label or small pilot studies and individually do not
provide a reliable template on which to base eﬀective
strategies for improving treatment of patients with hep-
atitis C after liver transplantation. As such, several piv-
otal issues regarding management of hepatitis C afterPublished by Elsevier B.V. All rights reserved.
M. Berenguer / Journal of Hepatology 49 (2008) 274–287 275transplantation are unanswered, including identiﬁcation
of the most eﬀective dosing regime, the optimal use of
growth factors, the best timing to initiate treatment,
and how to mitigate the risk for allograft rejection.
The aim of this systematic review is to provide a syn-
thesis of the current literature regarding treatment of
recurrent hepatitis C with PEG-IFN plus ribavirin either
in the acute or chronic phase of the disease.2. Materials and methods
2.1. Study selection criteria
2.1.1. Search strategy
Bibliographic searches were performed in MEDLINE (January
2002 to January 2007) for the following words (all ﬁelds): (‘‘Hepatitis
C” [MeSH] or ‘‘Hepatitis C virus” or HCV) and (‘‘Liver transplanta-
tion” [MeSH]) and (‘‘pegylated interferon” [MeSH] or ‘‘peginterferon”
or ‘‘interferon”) and (‘‘ribavirin” [MeSH]). Reference lists of the clin-
ical trials identiﬁed during electronic searching were also hand
searched to identify additional relevant trials for inclusion. Abstracts
of the articles selected were reviewed, and those satisfying the inclusion
criteria were included in the analysis.
2.1.2. Selection of studies
Studies eligible for inclusion in this analysis describe the treatment
of established recurrent hepatitis C with either PEG-IFN alfa-2a (Peg-
asys, Hoﬀman-La Roche, Nutley, New Jersey) or PEG-IFN alfa-2b
(PegIntron; Schering-Plough Corp., Kenilworth, New Jersey) plus
ribavirin. Hepatitis C was deﬁned by detectable HCV RNA (as indi-
cated by polymerase chain reaction [PCR]-based assay) and histologic
evidence of acute or chronic hepatitis on graft biopsy.
All studies were required to clearly state the number of liver trans-
plant recipients infected with HCV who received therapy with PEG-
IFN alfa plus ribavirin. Studies of liver transplant recipients treated
preemptively, that is, before histologic evidence of recurrent HCV
infection, were excluded. In addition, studies that included patients
treated with standard IFN, patients not receiving ribavirin, or patients
coinfected with HCV and HIV were excluded. Studies published in
abstract form only, or in non-English language were excluded. In addi-
tion, articles published in Transplantation Proceedings were also
excluded due to the brief nature of these reports.
2.1.3. Assessment of study quality and data extraction
All studies evaluated SVR in liver transplant recipients with recur-
rent hepatitis C who were receiving PEG-IFN and ribavirin. From
each study, the following predeﬁned variables were extracted: author,
country, patients who could be evaluated, inclusion and exclusion cri-
teria, study design (retrospective vs. prospective; controlled vs. uncon-
trolled), baseline patient characteristics (age and sex distribution),
HCV genotype distribution, time from liver transplantation, type of
liver disease (acute hepatitis vs. chronic hepatitis vs. cholestatic hepa-
titis), degree of liver disease (ﬁbrosis stage and activity score), type of
immunosuppressant (tacrolimus, cyclosporine, prednisone, mycophen-
olate mofetil, sirolimus), body mass index (BMI), history of therapy
with IFN or IFN plus ribavirin, viral load, alanine aminotransferase
(ALT) levels, renal insuﬃciency, treatment regimen (dose of PEG-
IFN alfa-2a or PEG-IFN alfa-2b, dose of ribavirin, duration of ther-
apy), and outcome measures.
2.1.4. Outcome measures
The primary outcome measure in this analysis was SVR, deﬁned as
undetectable serum HCV RNA at least 24 weeks after completion of
therapy. Secondary end points included biochemical response (BR;
deﬁned as the normalization of serum ALT levels at the end of treat-
ment), early virologic response (EVR), end-of-treatment virologicresponse (ETVR; deﬁned as undetectable HCV RNA at the end of
therapy), histologic response (changes in ﬁbrosis and in liver histologic
activity), SVR according to genotype, and tolerability (premature
treatment discontinuation, dose reduction, rejection, mortality, and
use of growth factors).3. Results
3.1. Study characteristics
Two studies identiﬁed by the search strategy were
excluded from the calculations of this systematic review
because they were published in Transplantation Proceed-
ings [31,32].
Nineteen studies were eligible for inclusion in this
analysis (Fig. 1 and Table 1) [13–30]. Studies were con-
ducted primarily in Europe (n = 12) and the United
States (n = 6), with one Canadian study, and all studies
were published between 2004 and 2007 (2004, n = 4;
2005, n = 3; 2006, n = 7; 2007, n = 5).
Most studies were retrospective and consisted of a
review of hospital experience in treating liver transplant
recipients who had established recurrent hepatitis C.
Conversely, there were no randomized comparative
studies of PEG-IFN alfa plus ribavirin versus placebo
or no treatment. In only one study, patients with recur-
rent mild disease were randomized to treatment versus
placebo while all patients with severe recurrence were
treated [30]. Where documented in these studies,
approximately 50% of the screened patients subse-
quently received treatment. Inclusion criteria were gen-
erally homogeneous across all studies and included
detectable HCV RNA, elevated serum transaminase lev-
els, and histologic ﬁndings consistent with chronic liver
damage of diﬀerent degrees. Two studies evaluated the
treatment of patients with recurrent acute lobular hepa-
titis [26,28].
3.2. Patients evaluated
A total of 611 liver transplant recipients treated with
PEG-IFN alfa and ribavirin were included in the 19
studies (Table 2). The median age was 53.8 years (range,
48.5–61.4 years) and was higher in Italian and Spanish
studies (median, 56.5 years; range, 52.2–61.4 years).
Most patients were male (n = 436, 71.4%), infected with
HCV genotype 1, (n = 524, 85.8%), and had not previ-
ously received PEG-IFN alfa plus ribavirin antiviral
therapy (n = 328/445, 73.7%). Only six studies provided
the BMI (mean, 25.12 kg/m2) and one additional study
provided a mean patient body weight of 75 kg [25]. Anti-
viral therapy was generally started 1–3 years after trans-
plantation (mean time from liver transplantation to
therapy, 24.3 months; range, 1–157 months). Baseline
immunosuppression was mainly based on tacrolimus
(n = 403, 65.9%), and most patients had discontinued
Studies published in English referring to treatment 
of established recurrent hepatitis C with 
PEG-IFN alfa + RBV (n=21)
2 studies excluded
19 studies including 611 patients
receiving PEG-IFN alfa + RBV therapy
17 nonrandomized studies2 prospective, 
randomized studies
SVR rates
Untreated patients 0/27 (0%)
PEG-IFN alfa + RBV 25/75 (33%)
9 prospective studies 8 retrospective studies
SVR 
PEG-IFN alfa + RBV: 101/315 (32%)
SVR
PEG-IFN alfa + RBV: 64/221 (29%)
Fig. 1. Study ﬂow diagram.
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erate liver disease in most patients, whereas few patients
had cirrhosis or ﬁbrosing cholestatic hepatitis. For most
studies, renal function was preserved within the cohorts
selected (in 10 studies, patients with renal impairment
were excluded).
3.3. Antiviral therapy
PEG-IFN alfa-2b was used in 16 studies, PEG-IFN
alfa-2a was used in six studies and both agents were used
in three studies (Table 3). In 11 of 19 studies, the full
dose of PEG-IFN alfa was chosen as the starting dose.
Ribavirin was generally initiated at a dose of 600–
800 mg per day, although ﬁve studies initiated ribavirin
at doses of 400 mg per day or less. Growth factors were
used in most studies (13/19) to help minimize the need
for dose reduction or discontinuation of PEG-IFN alfa
and/or ribavirin. Only one study permitted the use of
erythropoietin but excluded the use of granulocyte col-
ony-stimulating factor (GCSF) [23]. The intended dura-
tion of therapy was 12 months (or 48 weeks) in 13
studies. Of the remaining six studies: the duration of
treatment was varied in four according to genotype
(genotype 2/3, 6 months; genotype 1/4, 12 months);
treatment was continued in one for 48 weeks after
HCV RNA became undetectable; and treatment was
administered indeﬁnitely in one study.
3.4. Eﬃcacy and tolerability of antiviral therapy
ETVR and biochemical responses were 42.2% (17–
68%) (n = 18) and 54.8% (23–75%) (n = 15), respec-
tively. SVR was attained in 30.2% (0–50%) of treated
patients. Determination of SVR according to viral geno-type was heavily inﬂuenced by the large proportion of
genotype 1 patients included in these studies. In total,
10 of 19 studies reported virologic outcomes in genotype
1 patients with a mean SVR rate of 28.7% (range 12.5–
40%). SVR rates amongst other genotypes were variable
probably due to the small number of patients available
for analysis. However, SVR rates in non-genotype 1
patients were universally higher than in genotype 1
patients: in mixed non-G1 populations SVR rates ran-
ged from 60% to 75%, whilst the limited number of stud-
ies which reported data indicate SVR rates of 71–100%
in G2 patients and 66.7–100% in G3 patients (Table
4). In addition, in 2 studies, infection with HCV geno-
type 2 was found to be an independent predictor of
SVR in the multivariate analysis. Premature discontinu-
ation of therapy occurred in 27.6% of treated patients,
without major diﬀerences between centers where growth
factors were, and were not, allowed (25.4% vs. 33.9%).
More speciﬁcally, in 13 studies where EPO was used,
the SVR was 33%, not statistically diﬀerent from a rate
of 29% described in 5 studies where it was not used. In
turn, ﬁlgastrim was used in 11 studies with a SVR of
34% compared to 29% in 7 where it was not used. If
we exclude the studies focusing on acute hepatitis stud-
ies, there was a trend to better results, both in terms of
SVR and rate of discontinuation, over time. In fact, the
rate of SVR was 19.7% (range: 0–45%) in 2004–2005
studies compared to 35.2% (range: 23–50%) in those
published in 2006–2007. In turn, the rate of discontinu-
ation in these chronic hepatitis studies was 37% (range:
20–58%) in earlier studies compared to 28% (range: 4–
47%) in 2006–2007 studies. These results possibly reﬂect
the learning process and greater use of growth factors.
Causes of treatment discontinuation included cyto-
penia (particularly anemia), neuropsychiatric condi-
Table 1
Study characteristics
Author Year Country Type of study Patients
screened (n)
Patients
included
(n)
Inclusion criteria Exclusion criteria
Rodriguez-
Luna et al. [15]
2004 US P, U 56 19
(+18 on
therapy)
HCV RNA+, CH (Ishak
ﬁbrosis >2 or activity score
>6/18) or FCH
Rejection, sepsis, Hgb
<8 mg/dL, neutrophil
count <750/lL, severe
depression, creatinine
clearance <30 mL/min
Neﬀ et al. [16] 2004 US R, U NA 57 HCV RNA+, abnormal
ALT, CH on liver biopsy,
age >18 years
Re-LT, other organ
transplants, coexistent liver
disease
Ross et al. [13] 2004 US R, U 31 16 HCV RNA+, abnormal
ALT, CH on liver biopsy
NA
Dumortier et al. [14] 2004 France P, U NA 20 HCV RNA+, CH
(METAVIR: FP 1 and/or
A P2)
NA
Babatin et al. [18] 2005 Canada R, U NA 13 HCV RNA+, abnormal
ALT, CH on liver biopsy
Activity score <1
Toniutto et al. [17] 2005 Italy R, U NA 12 HCV RNA+, abnormal
ALT, CH on liver biopsy
(Ishak >2)
HBV coinfection, normal
ALT, rejection
Castells et al. [26] 2005 Spain P, C 46 24 HCV RNA+, acute hepatitis
on liver biopsy, abnormal
ALT, genotype 1
Rejection, normal ALT,
renal failure, nonadherent
patients
Biselli et al. [29] 2006 Italy R, U NA 20 HCV RNA+, abnormal
ALT, CH on liver biopsy,
age >18 years
HBV coinfection, normal
ALT, creatinine >2 mg/dL
Hgb <11 g/dL, time from
LT <6 months
Berenguer et al. [20] 2006 Spain R, U NA 36 a HCV RNA+, CH on liver
biopsy, age >18 years
Coexistent graft disease
(vascular, biliary,
autoimmune or infectious
conditions), history of
heart disease
Oton et al. [21] 2006 Spain P, U NA 55 HCV RNA+, abnormal
ALT >6 months, CH
without rejection (F > 1
Ishak or lobular hepatitis),
adults, >1-year post-LT,
steroid withdrawal
>6 months, no change in IS
within 3 months
HIV, severe cholestatic
recurrence, creatinine
>2.2 mg/dL, severe
cardiopulmonary disease,
Hgb <10 g/dL, neutrophil
count <1200/lL, platelet
count <50,000/lL
Mukherjee et al. [31] 2006 US R, U 38 32 HCV RNA+,
ALT > 1.5  ULN, CH
without rejection
(inﬂammation or steatosis),
19 P age 6 75 years
Rejection, renal transplant,
other graft injuries, Hgb
<10 g/dL, neutrophil count
<1500/lL, platelet count
<50,000/lL, creatinine
>1.8 mg/dL
Mukherjee et al. [22] 2006 US P, U 48 39 HCV RNA+, ALT > 1.5
ULN, CH without rejection
(inﬂammation or steatosis),
19 P age 6 75 years
Rejection, renal transplant,
other graft injuries, Hgb
<10 g/dL, neutrophil count
<1500/lL, platelet count
<50,000/lL, creatinine
>1.8 mg/dL, severe
depression
Fernandez et al. [23] 2006 Spain P, U 88 47 HCV RNA+, ALT > 45 IU/
L, CH without rejection in
liver biopsy within 2 months
(FP 2 or
F = 1 + HAIP 3), age
>18 years, IFN-naive post-
LT
Normal ALT, biliary/
vascular complications,
Hgb <10 g/dL, neutrophil
count <1500/lL, platelet
count <65,000/lL,
creatinine clearance
<35 mL/min, renal
transplantation, severe
depression, ischemic
cardiopathy
(continued on next page)
Line missing
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Table 1 (continued)
Author Year Country Type of study Patients
screened (n)
Patients
included
(n)
Inclusion criteria Exclusion criteria
Neumann et al. [24] 2006 Germany P, U NA 25 HCVRNA+, ALT > 2–3
ULN, CH without rejection
in liver biopsy within
6 months, >1-year post-LT
Hgb <10 g/dL, WBC <2500/
lL, platelet count <60,000/
lL, decompensated liver
disease, autoimmunity,
major comorbidity or
psychiatric conditions
Picciotto et al. [25] 2007 Italy P, U 123 61 HCV RNA+, ALTP 2
ULN, CH without rejection
in liver biopsy within
3 months (inﬂammation)
Neutrophil count <1000/lL,
platelet count <50,000/lL,
Ishak <2, creatinine >2 mg/
dL, decompensated liver
disease, ANA >1:320,
inadequate compliance,
major comorbidity or
malignancy
Angelico et al. [29] 2007 Italy P, C
(1 arm
with
PEG-IFN
monotherapy)
50 42 (21
treated
with
PEG-
IFN
+ RBV
Age 670 years, HCV
RNA+, increased ALT, CH
in liver biopsy within
6 months (Ishak FP 1 and
F < 5), >1-year post-LT
Antiviral therapy post-LT,
Hgb <12 g/dL, WBC <3000/
lL, platelet count <70,000/
lL, creatinine P2 mg/dL,
HIV, HBV, alcohol or drug
consumption, cirrhosis,
autoimmune hepatitis, major
comorbidity or malignancy
Carrio´n et al. [30] 2007 Spain P, C 140 81
(54
treated)
18 6 age 6 70 years, HCV
RNA+, chronic hepatitis on
biopsy
HIV, HBV,
contraindications for IFN or
RBV, prior organ
transplantation, creatinine
clearance <20 mL/min
Sharma et al. [27] 2007 US R, U NA 35 HCV RNA+, chronic
hepatitis on biopsy (Ishak
F > 1), increased ALT
Rejection or biliary problems
Zimmermann
et al. [28]
2007 Germany P, U 53 26 HCV RNA+, acute hepatitis
on liver biopsy, abnormal
ALT
Rejection, CMV infection or
biliary problems; re-LT for
rejection or HCV, HIV, or
HBV coinfection; normal
ALT; major comorbidity or
malignancy; creatinine
P2 mg/dL; ANC <1500/lL;
platelet count <50,000/lL;
Hgb <10 g/dL (women) or
<10.5 g/dL (men); bilirubin
>5 mg/dL
ALT, alanine aminotransferase (IU/L); CH, chronic hepatitis; C, controlled; FCH, ﬁbrosing cholestatic hepatitis; HAI, hepatic activity index; HBV,
hepatitis B virus; Hgb, hemoglobin; IFN, interferon; IS, immunosuppression; LT, liver transplantation; NA, not available; P, prospective; PEG-IFN,
pegylated interferon; R, retrospective; U, uncontrolled; WBC, white blood count;
a Study based on 67 liver transplant recipients treated with standard IFN + RBV or PEG-IFN + RBV. Speciﬁc data on the 36 patients treated with
PEG-IFN and RBV available directly from the author.
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rejection episodes. Despite the use of adjuvant therapy
with growth factors, dose reductions were necessary in
the majority of patients (68%; PEG-IFN alfa: 39.4%;
ribavirin: 54.4%). Overall, the incidence of rejection
was low at about 6.4% and ranged from 0% to
25%. Fourteen studies provided data on the potential
impact of antiviral therapy on histologic progression
(Table 4). However, these data were presented hetero-
geneously among studies; histologic scoring systemsdiﬀered among studies; and only a minority of
patients underwent liver biopsy prior to, and after,
antiviral therapy. The deﬁnition of improvement or
worsening of histologic activity was also diﬀerent
among studies. In studies that diﬀerentiated the histo-
logic eﬀect in SVRs of nonresponders, an improve-
ment in the stage of ﬁbrosis and the
necroinﬂammatory grade was observed in SVRs,
whereas disease progression was generally observed
in nonresponders.
Table 2
Patient baseline characteristics
Author Age
(years)
Sex
(M/F)
BMI (range)
(kg/m2)
Naive patients/
prior NRs (n)
Time since LT
(range)
(months)
(range)
Patients with
genotype
1/non-1 (n)
Viral load (IU/mL) Patients
taking
CyA/
Tac (n)
Rodriguez-
Luna et al. [15]
53 ± 7 14/5 NA NA 4.2 (1.0–16.2) 12/7 1,571,941 ± 2,382,580 3/15
Neﬀ et al. [16] 52 (32–70) 39/18 NA 29/28 23.5 (1.6–84.7) 56/1 >850,000 in 39 (68%) 0/57
Ross et al. [13] 51.4 ± 9.6 7/9 NA 4/12 9.5 11/5 0.76 ± 0.44  106 IU/mL 0/16
Dumortier et al. [14] 53.8 (39–66) 13/7 NA 18/2 28 (3–103) 16/4 5.9 (0.5–10.1) million copies/mL 3/17
Babatin et al. [18] 49.4 (39.4–61.3) 10/3 NA 12/1 24 (6–73) 6/7 NA 7/3
Toniutto et al. [17] 56.5 (23–63) 6/6 23 (18–35) NA 14.0 (0.6–60.8 12/0 NA 1/11
Castellls et al. [26] 61.4 ± 8.1 17/7 NA 19/5 3.8 ± 2.2 24/0 6.1  107(8.1  104  1.6  108) 0/24
Biselli et al. [29] 60 (40–67) 11/9 25.8 (20–40.6) 10/10 56.5 (13.0–157.0) 16/4 2.4 (0.01–22.8) mEq/mL 11/9
Berenguer et al. [20] 55 (30–67) 25/11 26 (17.5–38) 27/9 16.6 (2.7–132.6) 32/4 500 000 (21,400–7,700,000) 15/21
Oton et al. [21] 54.3 ± 9.7 44/13 25.9 ± 3.4 49/6 63.3 ± 45.5 50/5 997 780 ± 758 579 18/34
Mukherjee et al. [31] 49.9 (16.8–61.8) 22/10 NA 29/3 16 (2–70) 24/8 2,800,000 (111,055–8,500,000) 10/22
Mukherjee [22] 50.4 (36–70.9) 33/6 NA 31/8 20 (2–168) 31/8 1 700,000 (4,780,000–7,500,000) 24/15
Fernandez et al. [23] 52.2 ± 9.2 28/19 NA 44/3 32 ± 25 44/3 3 519 482 (31,000–200,000,000) 12/35
Neumann et al. [24] 49.2 (26–68) 20/5 75 (50–130) 14/11 38 (2–108) 20/5 >1,000,000 in 14 3/22
Picciotto et al. [25] 54 (41–68) 48/13 NA NA 25 (3–131) 53/8 1115  106 (0003–8000) 33/28
Angelico et al. [29] 59 ± 5 15/6 26.4 ± 1.4 NA 48 ± 29 17/4 156  104 10/9
Carrion et al. [30] 59 (31–70) 40/14 NA NA 14.5 (2.0–38.0) 50/4 6.5 log10 IU/mL (4.5–7.7) 22/29
Sharma et al. [27] 48.5 (36–62) 27/8 NA 24/11 16.0 (1.5–129.0) 27/8 6.4 (4.4–7.6) log10 15/20
Zimmermann
et al. [28]
57.9 ± 9.3 17/9 23.6 ± 4.2 18/8 9.4 ± 3.6 23/3 6.9 ± 7.4 log10 5/16
Author Patients taking
MMF/Sir (n)
P AH FCH Fibrosis score Cirrhosis
n (%)
Activity score ALT levels (IU) Creatinine
(mg/dL)
Rodriguez-
Luna et al. [15]
4/2 NA NA Yes (n?) 2.15 ± 1.67 NA 5.22 ± 3.11 2.37 ± 0.758  ULN NA
Neﬀ et al. [16] 0/0 NA NA NA F1 = 15,
F2 = 32,
F3 = 10
0 NA NA NA
Ross et al. [13] 0/0 NA NA 2 NA NA NA NA 1.24 ± 0.20
Dumortier
et al. [14]
12/0 2 0 0 2.2 (1–3) 0 1.8 (1.0–3.0) 2.4 (1–6.5)  ULN NA
Babatin et al. [18] 0/4 0 0 F0 = 1,
F1 = 2,
F2 = 5,
F3 = 3,
F4 = 2
2 Mild = 1,
moderate = 7,
severe = 5
248 (70–553) NA
Toniutto et al. [17] 0/0 NA NA 0 1 (0–6) NA 4 (2–6) 126 (39–920) NA
Castellls et al. [26] 7/0 24 100% No – 0 – 287 ± 222 1.13 ± 0.15
Biselli et al. [29] 0/0 1 No No 2 (1–3) 0 10 (6–15) 111.5 (52–361) 1.3 (0.6–2.0)
Berenguer et al. [20] 3/0 5 Yes
(n = 2)
Yes F1–2 = 10,
F3–4 = 24
4 (11) Mild = 2,
moderate = 15,
severe = 17
166 (26–1547) NA
Oton et al. [21] 5/0 0 0 0 3.6 ± 2 18 NA 185.9 ± 115.8 NA
Mukherjee et al. [31] 0/2 All patients
(5–10 mg)
0 NA NA NA NA 209 (91–672) NA
Mukherjee [22] NA NA NA NA NA NA NA 122 (71–487) NA
Fernandez et al. [23] 0/0 NA NA 10 1.6 ± 0.9 F3–4 = 8 PI = 2.6 ± 0.8;
LI=2.7 ± 0.7.
201 ± 151 NA
Neumann et al. [24] 11/0 0 0 0 F0 = 3,
F1 = 5,
F2 = 9,
F3 = 8
0 Mild: n = 0;
moderate: n = 8;
severe: n = 17
49 (40–174) NA
Picciotto et al. [25] 9/0 0 0 0 F1 = 10,
F2 = 21,
F3 = 18,
F4 = 10
10 NA NA NA
Angelico et al. [29] 0/0 0 0 0 2 ± 1 0 4 ± 1 117 ± 73 NA
Carrion et al. [30] NA/2 NA NA 4 F0–1 = 21,
F2 = 22,
F3–4 = 11
NA <4: n = 16P 4:
n = 38
147.5 (27–712) NA
Sharma et al. [27] 10/0 4 0 1 2 (1–6) NA 7 (4–12) 209 (62–633) 1 (0.7–1.6)
Zimmermann
et al. [28]
4/1 22 26 0 NA 0 2.40 ± 1.88 (Ishak) 157 ± 149 1.08 ± 0.27
AH, acute hepatitis; BMI, body mass index; CyA, cyclosporine; FCH, ﬁbrosing cholestatic hepatitis; F, female; LI, lobular inﬂammation; LT, liver
transplantation; M, male; MMF, mycophenolate mofetil; NA, not available; NR, nonresponder; P, prednisone; PI, portal inﬂammation; Sir,
sirolimus; Tac, tacrolimus; ULN, upper limit of normal.
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Table 3
Treatment characteristics
Author PEG-IFN alfa-2b (n/dose) PEG-IFN alfa-2a (n/dose) RBV dose (mg/day)
Rodriguez-Luna et al. [15] 0.5–1.5 lg/kg per week (n = 19) – 400 then titrated to 800–1000
Neﬀ et al. [16] 1.5 lg/kg/week (n = 57) 0 400–600
Ross et al. [13] 1.5 lg/kg/week (n = 16) 0 800–1200
Dumortier et al. [14] 0.5–1 lg/kg per week (n = 20) 0 400
Babatin et al. [18] 0.9 lg/kg/week (n = 13) 0 660
Toniutto et al. [17] 0.5 lg/kg/week (n = 12) 0 600–800
Castells et al. [26] 1.5 lg/kg/week (n = 24) 0 600
Biselli et al. [29] 1 lg/kg/week (n = 20) 0 600
Berenguer et al. [20] 1.5 lg/kg/week (n = 13) 180 lg/week (n = 23) 600–1200
Oton et al. [21] 1.5 lg/kg/week (n = 51) 180 lg/week (n = 4) 800–1200
Mukherjee et al. [31] 0 180 lg/week (n = 32) 800 then titrated to 1000–1200
Mukherjee et al. [22] 1.5 lg/kg/week (n = 39) 0 800
Fernandez et al. [23] 1.5 lg/kg/week (n = 47) 0 600–800
Neumann et al. [24] 1 lg/kg/week (n = 25) 0 600
Picciotto et al. [25] 1 lg/kg/week (n = 61) 0 600–800
Angelico et al. [29] 0 180 lg/week (n = 21) 200 then increased by 100 up to a
maximum tolerated level
Carrion et al. [30] 1.5 lg/kg/week (n = 54) 0 400–1200 adjusted for creatinine
clearance
Sharma et al. [27] 1.5 lg/kg/week
(No. of patients not stated)
180 lg/week (No. of patients not stated) 800
Zimmermann et al. [28] 0 90 lg/week for 4 weeks then escalated
to 135–180 lg/week (n = 26)
600 (started at 5th week) then
increased to 800–1200 if tolerated
Author Duration (months) EPO Filgastrim Transfusions
Rodriguez-Luna et al. [15] 12 months after HCV RNA negativity Yes Yes Yes
Neﬀ et al. [16] 12 Yes Yes Yes
Ross et al. [13] Indeﬁnitelya Yes Yes NA
Dumortier et al. [14] 12 No No NA
Babatin et al. [18] 12 Yes No NA
Toniutto et al. [17] 12 No No NA
Castells et al. [26] 12 Yes Yes Yes
Biselli et al. [29] 12 Tx was D/C in patients with <2log10 drop in HCV RNA at month 6) Yes Yes Yes
Berenguer et al. [20] 12 Yes Yes Yes
Oton et al. [21] G1 and 4: 12; G2 and 3: 6 Yes Yes Yes
Mukherjee et al. [31] G1 and 4: 12; G2 and 3: 6 Yes Yes Yes
Mukherjee et al. [22] G1 and 4: 12; G2 and 3: 6 No No Yes
Fernandez et al. [23] 12 Yes No Yes
Neumann et al. [24] 12 Yes Yes NA
Picciotto et al. [25] G1 and 4: 12; G2 and 3: 6 No No Yes
Angelico et al. [29] 12 No No No
Carrion et al. [30] 12 Yes Yes Yes
Sharma et al. [27] 12 Yes Yes Yes
Zimmermann et al. [28] 12 Yes Yes Yes
D/C, discontinued; HCV, hepatitis C virus; EPO, erythropoietin; G, genotype; NA, not available; PEG-IFN, pegylated interferon; RBV, ribavirin;
Tx, treatment.
a Discontinuation if HCV RNA+ at 6 months of therapy.
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An analysis of variables associated with virologic
response was conducted in 14 studies (Table 5). Vari-
ables typically included in these analyses were demo-
graphics (age, sex), baseline viremia, EVR at
3 months, genotype, immunosuppression type, baseline
histology, and duration of time from transplantation.
A few studies evaluated additional factors such as
body mass index, adherence to therapy, pretreatmentALT levels, history of interferon/ribavirin therapy,
and use of growth factors. Of these factors, those
most frequently associated with SVR were EVR at
3 months of therapy, infection with HCV genotype
2, adherence to therapy, and baseline viremia. Baseline
ﬁbrosis was found to be associated with SVR in the
univariate analysis only in 2 out of 10 studies that
included ‘‘baseline ﬁbrosis” as a potential predictive
factor. In none of these studies, this variable remained
in the multivariate analysis.
Table 4
Eﬃcacy and tolerability outcomes
Author ETVR, n (%) BR, n (%) SVR, n (%) SVR by genotype,
n/N (%)
D/C, n (%) Reasons for D/C (n)
Rodriguez-Luna
et al. [15]
7 (37) NA 5 (26) G1 < non-G1 7 (38) AR (1), psychosis (3), AI (1), FCH (1),
transaminase ﬂare (1)P < .04
Neﬀ et al. [16] 14 (25) 40 (70) 8 (14) – 18 (31.5) Depression (8), thrombocytopenia (1),
neutropenia (1), anemia (3),
noncompliance (1), rash (1), sinusitis (1),
confusion (1)
Ross et al. [13] (31) 12 (75) 0 (0) – 8 (50) Hematologic toxicity (6),
myelosuppression (1)
Dumortier et al. [14] 11 (55) 15 (75) 9 (45) – 4 (20) Thyroid disorder (1), depression (2),
asthenia (1)
Babatin et al. [18] 5 (38) 9 (69) 4 (31) G1: 1/8 (12.5) 7 (54) Neuropsychiatric eﬀects (3), myalgia (2),
CR (1), renal failure (1)G2: 2/2 (100)
G3: 0/1 (0)
G4: 0/1 (0)
G6: 1/1 (100)
Toniutto et al. [17] 2 (17) 3 (25) 1 (8) – 7 (58) Hematologic toxicity (5), thyroid
disorder (2)
Castells et al. [26] 14 (58) 16 (66) 8 (35) – RBV 3 (12.5) Severe anemia (3)
Biselli et al. [29] 9 (45) 7 (35) 9 (45) G1: 6/16 (37%) 1 (5) Pneumonia (1)
Non-G1: 3/4 (75%)
Berenguer et al. [20] 16 (44) 25 (69) 18 (50) G1: 19/62 (30.6) 17 (47) Anemia (5), rejection (5), poor
tolerability (2), others (5)Non-G1: 3/5 (60%)
Oton et al. [21] 36 (67) NA 24 (44) G1: 20/50 (40) 16 (29) Infection (6), poor tolerability (6),
depression (2), CR (1), cytopenia (1)G3: 2/2 (100)
G4: 1/2 (50)
Mukherjee et al. [31] 11 (34.3) 13 (46.9) 11 (34.3) – 5 (15.6) Fatigue (2), psychosis (1), lack of
insurance (1), thrombocytopenia (1)
Mukherjee et al. [22] 11 (28.2) 22 (56.4) 13 (33.3) – 17 (43.6) Fatigue (5), thrombocytopenia (3),
hepatic decompensation (3), anemia (2),
depression (1), psychosis (1), pleural
eﬀusion (1), hepatic artery thrombosis (1)
Fernandez et al. [23] 17 (36) NR 11 (23) – 10 (21) Self-discontinued (fatigue) (4), FCH (2),
AR (1), CR (1), cardiac insuﬃciency (1),
severe thrombocytopenia/neutropenia
(1)
Neumann et al. [24] 17 (68) 14 (56) 9 (36) G1: 30% 1 (4) HCC recurrence (1)
Non-G1: 60%
P = .21
Picciotto et al. [25] 21 (34) NA 17 (28) G1: 10/53 (18.9) 9 (15) Severe anemia (3), HCC recurrence (2),
severe neutropenia (1), AR (1), Bell’s
palsy (1), myocardial infarction (1)
G2: 7/8 (87.5)
Angelico et al. [29] 11 (52) 8 (38) 7 (33) G1: 10/25 (40) 7 (33) Headache (1), acute rejection (1),
asthenia (1), thrombocytopenia (1), liver
ﬂare (2), consent withdrawn (1)
G2: 5/7 (71)
Carrion et al. [30] NA 26 (48) 18 (33) G1 16/50 (32) 21 (39) Clinical decompensation (11), depression
(3), severe anemia (2), renal failure (2),
severe infection (2), chronic rejection (1)
Sharma et al. [27] 19 (54) 8 (23) 13 (37) G1: 9/27 (33.3) 15 (43) Depression (2), rejection and/or AIH (4),
dilated cardiomyopathy (1), cytopenias
(7), disabling myalgias/fatigue (1)
Zimmermann
et al. [28]
9 (35) NA 5 (19) G1: 3/23 (13) 3 Diarrhea (1), depression (2)
G3: 2/3 (66.7)
Author Dose reductions,
n (%)
Rejection,
n (%)
No. of patients
who died (%)
Causes of death Changes in ﬁbrosis Changes in activity
Rodriguez-Luna
et al. [15]
NR 1(5) 1 FCH SVR SVR
Improvement in
60%
Improvement in 100%
Unchanged in 20%, NR
Deterioration in
20%
Improvement in 40%
Neﬀ et al. [16] IFN 38 (67) NA 2 Sepsis (1), small-
bowel obstruction
(1)
39 Patients with
biopsy pre- & post-
LT
NA
RBV 22 (39)
Improved (18)
Unchanged (10)
Ross et al. [13] IFN 12 (75) NA 3 Sepsis (1),
multiorgan failure
(2)
Nine patients with
biopsy pre- and
post-LT
NA
RBV 13 (81) Worse (7)
Unchanged (2)
(continued on next page)
Line missing
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Table 4 (continued)
Author Dose reductions,
n (%)
Rejection,
n (%)
No. of patients
who died (%)
Causes of death Changes in ﬁbrosis Changes in activity
Dumortier et al. [14] RBV 13 (65) 5 (25) 0 – 2.2–1.6 1.8–0.3
IFN 6 (30)
Babatin et al. [18] 9 (72) 3 (23) 3 Renal failure (1),
liver failure (1),
Goodpasture
syndrome (1)
NA NA
Toniutto et al. [17] 11 (92) 0 0 – Stabilization in 6
(50%)
Improvement in 3 (25%)
Castells et al. [26] IFN 6 (25) 1 (4) 0 – NA NA
RBV 14 (58)
Biselli et al. [29] RBV 7 (35) 0 0 – No signiﬁcant
change
Improvement in 4/9
Berenguer et al. [20] 19 (53) 5 (14) NA – 15 patients with
biopsy pre- & post-
LT
Improvement (8)
Unchanged (7) Unchanged (4)
Worse (8) Worse (4)
Oton et al. [21] IFN 17 (31) 1 (2) 3 HAT, severe
cholangitis, lung
cancer (n = 1 each)
15 patients with
biopsy pre- and
post-LT
4SVR
RBV 17 (31) SVR: 2.4 ± 1.9 to
2.6 ± 1.3.
HAI: 7.5 ± 2.1 to 3.3 ± 2.8.
NR: 2.7 ± 1.7 to
3.7 ± 1.6.
NR
HAI: 7.1 ± 1.1 to 5.3 ± 3.2.
Mukherjee et al. [31] NA 0 1 NA Improvement (1) NA
Unchanged (6)
Worse (8) (15
patients with biopsy
pre- and post-LT)
Mukherjee et al. [22] NA 0 NA – Improvement (4) NA
Unchanged (10)
Worse (3)
Fernandez et al. [23] RBV 15 (32) 3 (6) 8 (17) FCH (3), CR (2),
HCC recurrence (1),
variceal bleeding
(1), HCV liver
failure (1)
16 patients with
biopsy pre- and
post-LT
SVR
NR No changes in HAI
PI: 2.2–2.4
LI: 2.3 to 2.1
Neumann et al. [24] IFN 15 (52) RBV 9
(36)
0 2 (8) post-LT HCC recurrence (1),
EBV (1)
Increase: 1.7–2.0 Decrease: 1.66–1.13
Picciotto et al. [25] 48 (79) 4 (6) 0a – NA NA
Angelico et al. [29] IFN 8 (38) 1 (5) 0 – Ten patients with
biopsy pre- and
post-LT
Improvement (2/10)
RBV 21 (100) Improvement (2) Worse (2/10)
Worse (7)
Carrion et al. [30] IFN 13 (24) 4 (7) 10 (18) Liver failure due to
disease progression
(10)
Improvement (11) NA
Unchanged (22)
RBV 36 (67) Worse (21)
Sharma et al. [27] Not stated 4 (11)b 0 – NA NA
Zimmermann
et al. [28]
17 patients 1 0 – NA NA
AI, autoimmunity; AR, acute rejection; BR, biochemical response; CR, chronic rejection; D/C, discontinued or discontinuation; EBV, Epstein–Barr virus; ET, end of treatment; FCH,
ﬁbrosing cholestatic hepatitis; HAI, hepatic activity; HAT, hepatic artery thrombosis; HCC, hepatocellular carcinoma; IFN, interferon; LI, lobular inﬂammation; LT, liver trans-
plantation; NA, not available; NR, nonresponse; PI, portal inﬂammation; RBV, ribavirin; R, rejection; SVR, sustained virologic response; Tx, treatment.
a Deaths during follow-up: in nonresponders (follow-up: 19 months), n = 14 (recurrent HCV); in SVR (follow-up: 24 months), n = 0.
b The 4 cases referred to in this study were diagnosed as rejection/autoimmune hepatitis.
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Development of hepatitis C after transplantation has
a negative impact on medium and long-term outcomes
among liver transplant recipients [1,2]. Strategies that
have been proposed to improve the results of liver trans-
plantation in HCV-infected patients include the eradica-
tion of HCV infection before transplantation with use of
antiviral therapy [3–7], the eradication of HCV infection
immediately after transplantation to prevent graft dam-age [3,8–10], and the treatment of established recurrent
hepatitis C in the acute or, more commonly, chronic
phase [11–32]. Although successful pretransplantation
antiviral therapy has been shown to prevent HCV rein-
fection, it can only be used in a small proportion of
patients and side eﬀects are numerous and potentially
life threatening [4–7]. In addition, immune globulins
are not eﬀective to universally prevent HCV recurrence.
In the only published study, 15 patients received human
hepatitis C immune globulin 75 or 150 mg/kg (Civacir,
Table 5
Predictive factors associated with SVR
Author Factors evaluated Predictive factors in univariate
analysis
Predictive factors in multivariate
analysis
Rodriguez-Luna et al. [15] NA Genotype 2 Genotype 2
Neﬀ et al. [16] NA NA NA
Ross et al. [13] NA NA NA
Dumortier et al. [14] Age, sex, genotype, baseline viremia,
completion therapy, PEG-IFN dose,
RBV dose, baseline ALT, baseline
histology, IS, VR at 3 months
Completion of therapy, genotype
non-1, VR at 3 months
NA
Babatin et al. [18] NA NA NA
Toniutto et al. [17] Age, sex, completion therapy, type of
steroid tapering, time from LT to Tx,
VR and BR at 3 and 6 months,
baseline activity and ﬁbrosis
NA Baseline activity score >5
Castells et al. [26] Age, sex, baseline viremia, VR at
3 months, CMV, baseline ALT, time
from LT to Tx, HCC, IS
VR at 3 months, absence of prior
steroid boluses, absence of prior
CMV
NA
Biselli et al. [29] Age, sex, IS, BMI, time from LT to
Tx, genotype, baseline viremia,
baseline histology, prior IFN
therapy, VR at 1 and 6 months, RBV
dose
VR at 1 and 6 months, NA
Berenguer et al. [20] Age, sex, BMI, baseline viremia,
genotype, donor age, baseline
histology, IS, EVR at 3 months, time
from LT to Tx, prior antiviral
therapy, use of EPO, use of
ﬁlgastrim, completion of therapy,
IFN and RBV dose
Use of EPO, VR at 3 months,
adherence to therapy (80  80  80)
VR at 3 months
Oton et al. [21] Age, sex, BMI, baseline HCV RNA,
IS, ﬁbrosis score, cirrhosis or not,
time from LT to Tx, VR at 1 and
3 months
Baseline HCV RNA (log10 IU/mL),
2–4 years after LT, VR at 1 and
3 months
Baseline HCV RNA (log10 IU/mL),
2–4 years after LT, VR at 1 and
3 months
Mukherjee et al. [31] Sex, age, baseline viremia, IS,
ﬁbrosis, HAI, time from LT,
genotype, VR at 3 months, ALT,
bilirubin
VR at 3 months
Mukherjee et al. [22] Age, sex, donor HCV status, time
from LT, baseline viremia, bilirubin,
ALT and histology, genotype, EVR,
IS
EVR (P = .06) NA
Fernandez et al. [23] Sex, age, baseline HCV RNA,
immunosuppressive regimen, ﬁbrosis
score, baseline histology, time from
LT to Tx, history of cholestatic
hepatitis, ALT, GGT, FA, bilirubin,
genotype, VR at 3 months, complete
antiviral therapy (80  80  80)
Low GGT, low baseline viremia, VR
at 3 months, 80  80  80
NA
Neumann et al. [24] Not speciﬁed NA Baseline viremia <1,000,000 IU/mL
Picciotto et al. [25] Sex, age, baseline viremia, IS,
ﬁbrosis, time from LT to Tx,
genotype, HCC, associated HBV,AR
pretreatment, percentage dose PEG-
IFN and RBV, total dose IFN and
RBV
HCV genotype 2, higher doses of
antivirals, absence of cirrhosis
HCV genotype 2, total dose PEG-
IFN
Angelico et al. [29] NA VR at 3 months NA
Carrion et al. [30] Sex, age, donor age, baseline HCV
RNA, immunosuppressive regimen,
ﬁbrosis score, baseline histology,
ALT, bilirubin, genotype, VR at
3 months, BR, HVPG
Baseline bilirubin, mild vs. severe
hepatitis C recurrence, EVR, BR
EVR at 3 monthsa
(continued on next page)
Line missing
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Table 5 (continued)
Author Factors evaluated Predictive factors in univariate
analysis
Predictive factors in multivariate
analysis
Sharma et al. [27] Age, sex, baseline viremia, genotype,
donor age, baseline histology, IS,
EVR at 3 months, time from LT,
prior antiviral therapy, growth
factors, Tx adherence
Low baseline viremia, higher doses of
antivirals, longer Tx duration, EVR,
EPO, anemia
None remained in the multivariate
analysis
Zimmermann et al. [28] Age, sex, baseline viremia, genotype,
donor age, baseline histology, IS,
rejection, CMV infection, EVR at
3 months, time from LT, prior
antiviral therapy, Tx adherence
EVR, cumulative PEG-IFN dose NA
ALT, alanine aminotransferase; AR, acute rejection; BMI, body mass index; BR, biochemical response; CMV, cytomegalovirus; EPO, erythro-
poietin; EVR, early virologic response; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HVPG, hepatic venous
pressure gradient; IFN, interferon; IS, immunosuppression; LT, liver transplantation; NA, not available; RBV, ribavirin; Tx, treatment; VR,
virologic response.
a Factors were predictive of hemodynamic response which was correlated with SVR.
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[33]. Although patients receiving the high dose of hepa-
titis C immune globulin had lower alanine aminotrans-
ferase activity and lower HCV antigen levels in liver
tissue during treatment than the other groups, serum
HCV RNA levels did not diﬀer and infection recurred
in all patients. Early posttransplantation therapy (pre-
emptive therapy) administered during the ﬁrst 4–6 weeks
post-transplantation before there is clinical evidence of
liver damage has also been evaluated in several studies;
the results have been generally disappointing in terms of
antiviral eﬃcacy, applicability, and tolerability [8–
10,34]. The most widely used strategy involves initiating
antiviral therapy once the consequences of the recur-
rence of HCV infection are detected on liver biopsy. Ini-
tial studies based on monotherapy with IFN alfa yielded
poor results, with SVR rates lower than 5% [3]. With the
addition of ribavirin to IFN alfa therapy, there was a
noticeable improvement in treatment outcomes, with
viral eradication achieved in about 20% of treated
patients in the chronic phase of disease [3,11,12]. More
recently, PEG-IFN alfa in combination with ribavirin
has become established as the standard treatment for
chronic hepatitis C, and though, overall, the results
appear to have improved [13–32,34], a number of ques-
tions are unanswered regarding doses, duration of ther-
apy, necessity of adjuvant therapy (for instance with
growth factors), risk for rejection, and impact on liver
disease or patient survival.
This systematic review of clinical trials has revealed
certain important observations regarding the treatment
of hepatitis C after transplantation. Based on clinical
trial data, PEG-IFN alfa-2b plus ribavirin is the most
widely studied treatment. This regimen is used in a sim-
ilar manner to that adopted in nontransplant chronic
hepatitis C patients, with several important exceptions.
Treatment duration after transplantation is generally
instigated for a standard 12-month period, regardlessof HCV genotype, whereas in nontransplant patients,
those with HCV genotype 2/3 infection would be eligible
for a 24-week regimen.
Posttransplantation patients generally have a reduced
tolerance to ribavirin therapy, and this is reﬂected in the
lower starting ribavirin doses used after transplantation
than in nontransplant patients. Our review has revealed
that many studies initiated ribavirin at doses of 400–
600 mg per day and then increased doses slowly accord-
ing to patient tolerability. This is in contrast to the
nontransplant setting in which doses of at least 800 mg
per day are used [35,36]. We found that growth factor
supplementation was common among the selected stud-
ies, again indicating that patients after transplantation
may be particularly predisposed to the hematologic tox-
icities associated with therapy with PEG-IFN alfa plus
ribavirin. While a preemptive approach to managing
these tolerability concerns with use of erythropoietin
and GCSF was favored among the clinicians who con-
ducted these studies, we cannot ﬁrmly recommend this
approach based on published data. Probably this inter-
est for growth factors among physicians treating trans-
plant recipients reﬂects the high likelihood of
hematologic toxicity in this cohort. Overall, our analysis
suggests that, among posttransplantation patients
receiving PEG-IFN alfa plus ribavirin, approximately
68% will require dose reduction of one or both agents
to manage tolerability, and approximately one quarter
of all treated patients will ultimately discontinue treat-
ment because of unmanageable adverse events. Unfortu-
nately, we can not provide ﬁrm recommendations
regarding growth factors due to the heterogeneity and
reduced quality of published studies. However, based
on what we now know from the non-transplant setting,
all approaches that are being developed to enhance
adherence should be put in place in the transplant set-
ting (multidisciplinary approach, early recognition and
treatment of side eﬀects). In fact, the results from the
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a learning curve according to periods with better results
achieved in studies published in 2006–2007 than in those
published in 2004–2005. On closer examination though,
the times at which the patients were treated span a much
broader range. Most studies report on patients treated
between 2001 to 2004 or 2005. A couple of other studies
have earlier times of recruitment (during the 1990s) with
recruitment periods that span considerable periods. In
summary, while there appears to be a learning curve,
the data we have at present does not allow to conclude
that clinical outcomes have improved as clinical practice
has evolved.
Our analysis indicates that approximately one third
of patients receiving PEG-IFN alfa plus ribavirin attain
SVR after transplantation. Overall, this reinforces the
diﬃcult-to-treat nature of these patients and their gen-
eral refractoriness to therapy. Amongst nontransplant
patients, SVR rates of 54–56% are attainable, and, even
within the diﬃcult-to-treat genotype 1 cohort, SVR
rates are 42–46% [35,36]. An encouraging observation
from our systematic review relates to the predictability
of treatment outcomes. Our study indicates that it may
be possible to predict SVR using many of the same fac-
tors that are used in the nontransplant population, such
as EVR, treatment adherence, baseline viremia, and
infecting genotype. Indeed, among the small number
of patients with genotype 2/3 hepatitis C infection doc-
umented in these studies, SVR rates appear comparable
to those reported in treatment–naı¨ve genotype 2/3
patients. However, at this stage, the observational nat-
ure of these ﬁndings dictates that further prospective
research is necessary before these elements may be con-
sidered for use in routine clinical practice. Interestingly,
in none of the studies where it was assessed, baseline
ﬁbrosis was found to be independently associated with
SVR, suggesting that the same results can be achieved
independently of the degree of liver damage.
Eradication of the virus may not be the aim of treat-
ment in all patients. Our analysis clearly shows improve-
ment or lack of progression in necroinﬂammation
together with a high rate of biochemical response at
end of therapy (60%) among many treated patients.
Maintenance therapy with PEG-IFN alfa plus ribavirin,
even in the absence of SVR, may therefore represent an
important approach to limiting or even halting hepatic
deterioration. Careful consideration should be given to
discontinuing treatment in patients who do not show
declining viremia because these patients may still attain
considerable histologic beneﬁt from continued treat-
ment. In one study [30], the only variable independently
associated with histological response was antiviral ther-
apy. In this study, histological response occurred in only
8 (30%) untreated patients with mild recurrence com-
pared to 20 (74%) treated patients with mild recurrence.
In addition, among treated patients, variables associatedwith histological response were EVR, BR (ALT normal-
ization during therapy), and SVR. Interestingly, in
nonsustained virological responders, histological
response was more frequent in patients achieving a BR
(8 of 13) compared to those who did not (7 of 23). This
information would suggest that a beneﬁt might be
derived from maintenance therapy in patients who nor-
malize the transaminases with therapy. In a more recent
study on maintenance therapy, 21 liver transplant recip-
ients with recurrent hepatitis C received maintenance
therapy with interferon-alpha2b and ribavirin [37]. After
12 months of basic antiviral combination treatment, 14
(66%) patients had achieved on-treatment viral clear-
ance and 17 (81%) a BR. Interestingly, the degree of
inﬂammation declined signiﬁcantly and in virologic
responders, maintenance therapy led to further regres-
sion of inﬂammation and also of ﬁbrosis. While recent
data from the immune competent population (HALT
study presented at the recent AASLD meeting) would
suggest that this strategy is not eﬀective at halting dis-
ease progression, it appears that further studies are
required to assess its potential beneﬁts in the transplant
population.
Very few studies provided data on the outcome of
ﬁbrosing cholestatic hepatitis (FCH). In the only study
reporting the outcome of 10 patients with FCH [23], 2
recipients achieved a SVR, 2 nonresponders died from
progressive disease, one patient with an on-treatment
VR developed a rejection and had treatment discontin-
ued, and 5 achieved a BR without viral clearance.
Among these, 2 have continued therapy in the long-
term, whereas it was discontinued in 3 due to side eﬀects.
In these 3 patients, severe cholestatic hepatitis resumed
causing the death of one of the patients while in the 2
remaining patients, therapy was restarted and was fol-
lowed by a biochemical and clinical improvement. These
data would suggest that in patients with FCH, continu-
ous therapy might be indicated to avoid severe relapses.
There are some conclusions to be drawn from our
analyses. First, the eﬃcacy of antiviral therapy in liver
transplant recipients is lower than that in the nontrans-
plant population. This reduced eﬃcacy is possibly
related to the diﬃculty in maintaining full doses of
PEG-IFN alfa and particularly ribavirin throughout
the treatment period. It would therefore appear that
improvement in monitoring and management of side
eﬀects, particularly hematologic cytopenias and psychi-
atric complications, would be useful in optimizing treat-
ment outcomes. The rationale for the use of growth
factors will also likely beneﬁt transplant recipients
undergoing antiviral therapy [37–41]. Second, the obser-
vation that a substantial proportion of patients attain a
biochemical response and that posttreatment liver biop-
sies generally show an improvement (or at least lack of
progression) in histologic activity indicates that mainte-
nance therapy has potential beneﬁt in this setting. This
Table 6
Summary of the critical aspects of antiviral therapy for recurrent
hepatitis C
– Combination therapy with pegylated interferon and ribavirin.
– Doses: same as those used in the non-transplant setting.
Ribavirin dosage based on creatinine clearance
– Duration: at least 6 months following HCV-RNA negativization.
– Time of initiation: chronic hepatitis C with a least moderate
ﬁbrosis (ﬁbrosis P2).
– Multidisciplinary approach to optimize full dose antiviral therapy.
– Use of growth factors to minimize dose reduction
and/or discontinuation.
– Maintenance therapy for ﬁbrosing cholestatic hepatitis unless
a sustained virologic response is achieved.
– Early virologic response as a predictor of nonresponse.
– Greater eﬃcacy in non-1 genotypes.
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tion in a manner similar to that being considered for
immune-competent patients (ie. using low dose PEG-
IFN alfa to prevent the complications of chronic liver
disease) [42]. Finally, predictive factors, particularly
viral kinetics, and most speciﬁcally viral response
assessed at 3 months of treatment initiation, are useful
tools to identify patients with poor tolerability or those
who are candidates for treatment discontinuation. Con-
versely, predictive factors may also help identify patients
who should maintain full therapeutic doses, for which
the chances of obtaining SVR are high.
In conclusion, improvements have been made in the
use of therapy with PEG-IFN alfa and ribavirin, both
in transplant recipients and nontransplant patients.
Table 6 summarizes the critical aspects of antiviral ther-
apy for recurrent hepatitis C. Unfortunately, many
questions remain unanswered with regard to transplan-
tation because of the lack of well-designed, large, pro-
spective studies and the signiﬁcant heterogeneity
within the studies that have been published.
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